Dosage and duration of medication for men with lower urinary tract symptoms: Two questions without definitive answers

Current Opinion in Urology

Volumn 16, Issue 1, 2006, Pages 37-39

  Desgrandchamps, François ^a   Mongiat Artus, Pierre ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Benign prostatic hyperplasia; Medication dosage; Treatment duration

Indexed keywords

ALFUZOSIN; ANDROSTANOLONE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; HIGH RISK PATIENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URETHRA DISEASE; URINARY TRACT DISEASE;

ADRENERGIC ALPHA-ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MALE; PROSTATIC HYPERPLASIA; STEROIDS;

EID: 29944442713     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46:547-554.
2. AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170:530-547.
3. de Reijke TM, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004; 93:757-762.
4. Fawzy A, Vashi V, Chung M, et al. Clinical correlation of maximal urinary flow rate and plasma doxazosin concentration in the treatment of benign prostatic hyperplasia. Urology 1999; 53:329-335.
5. Roehrborn CG, Oesterling FE, Auerbach S, et al. The hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 1996; 47:159-168.
6. Abrams P, Speakman M, Stott M, et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate selective aA-adrenoreceptor antagonist, in patients with benign prostatic hyperplasia. Br J Urol 1997; 80:587-596.
7. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160:1701-1706.
8. Clark RV, Hermann DJ, Cunningham GR, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89:2179-2184.
9. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74:505-508.
10. Giannakopoulos X, Baltogiannis D, Giannakis D, et al. The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv Ther 2002; 19:285-296.
11. Eri LM, Tveter KJ. Patient recruitment to and cost of a prospective trial of medical treatment for benign prostatic hyperplasia. Eur Urol 1992; 22:9-13.
12. Lowe FC, Batista J, Berges R, et al. Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion. Prostate Cancer Prostatic Dis 2005; 8:206-209.
13. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002; 41:490-496.
14. Verhamme KM, Dieleman JP, Bleumink GS, et al. Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol 2003; 44:539-545.